drugset / Trial / NCT06482268
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
Phase 1
Recruiting
7 enrolled
University of California, San Diego
CiRA Foundation · collabKyoto University · collabSumitomo Pharma America, Inc. · collabSumitomo Pharma Co., Ltd. · collab
NaSingle-groupOpen-labelOther
Summary
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
Timeline
- Start
- 2024-06-01
- Primary completion
- 2025-02-28
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT1-DAP001 | Cell therapy | — | Other |